CSPC Pharmaceutical Group (HKG:1093) subsidiary, CSPC Megalith Biopharmaceutical, signed an exclusive licensing agreement with Radiance Biopharma for the development and commercialization of the Group's SYS6005 in the US, UK, and several other parts of the world, according to a Wednesday filing with the Hong Kong bourse.
CSPC Megalith will get an initial payment of US$15 million. The pharmaceutical may also receive potential development and regulatory milestone payments of up to US$150 million and potential sales milestone payments of up to US$1.08 billion, with a possibility of tiered royalties based on annual net sales of the Product in the Territory.
This drug uses a special enzyme-based technology to attach a powerful cancer-killing agent (MMAE) to an antibody, targeting cancer cells that have a protein called ROR1.
Other areas in the contract include Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.